Friday, January 9, 2026

Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug’s (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine.

SecureDose is reportedly initiating work on a novel manufacturing method for the commercial-scale production of cocaine, which will be produced to support safe supply programs.

“We have seen the proliferation of safe supply programs in both Canada and around the world. While opioid addiction is a serious problem, there exists a supply chain that provides both natural and synthetic opioid products for those programs,” commented Robert Steen, CEO of PharmaDrug.

“Cocaine, however, is the illegal drug that causes the most cost and harm to society barring opioids according to the Canadian Centre for Substance Use and Addiction, causing $4.2 Billion1 in harm in Canada annually – but there is no supply chain to alleviate these harms.”

READ: PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

A patent has been filed for a method of development that uses biosynthetic chemistry that the company believes will allow for the use of GMP manufacturing in the production of pharmaceutical grade cocaine. The intent is that the resulting product will be a reliable, regulated, clinically manufactured product that is suitable for use in safe supply programs.

A lab has already been identified by the company that will be used for the development of the novel process. An accelerated development timeframe is being pursued by the lab, with the manufacturing process to target the cost effective and efficient production of cocaine.

PharmaDrug last traded at $0.06 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why $100 Silver Right Now Would Be a Problem | Keith Neumeyer – First Majestic

Why Industrial Demand Is Changing the Silver Market | David Morgan

Gold and Silver Delivery Is Exposing the Paper Market | Andy Schectman

Recommended

Antimony Resources Drills 8.48% Sb Over 3 Metres, 2.07% Sb Over 27 Metres At Bald Hill

Steadright To Acquire 75% Interest In Moroccan Copper-Lead-Silver Project

Related News

PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

PharmaDrug (CSE: PHRX) this morning released a series of updates, headlined by the appointment of...
Tuesday, February 27, 2024, 09:44:15 AM

PharmaDrug Engages Research Lab To Advance Patented Cocaine Synthesis Method

PharmaDrug (CSE: PHRX) has formally engaged a research lab to refine and advance the development...
Tuesday, April 16, 2024, 09:31:23 AM

PharmaDrug: Biosynthetic Pharma-Grade Cocaine

PharmaDrug Inc (CSE: PHRX) last month revealed that it has begun work on developing a...
Sunday, April 7, 2024, 01:14:41 PM

PharmaDrug: A Path To Safe Supply

In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company's groundbreaking biosynthetic...
Wednesday, March 13, 2024, 01:30:00 PM

Who Is To Blame For The Growing Fentanyl Problem?

The United States is grappling with a relentless surge in fentanyl-related overdose deaths, marking a...
Sunday, February 11, 2024, 03:04:00 PM